Phathom Pharmaceuticals, Inc. files 10-Q

Phathom Pharmaceuticals reported increased product revenue of $58.3 million for the quarter ended March 31, 2026, up from $28.5 million in the prior year, driven by strong sales of its VOQUEZNA products. Despite revenue growth, the company incurred a net loss of $30.4 million, though this is a significant improvement from the $94.3 million net loss in the same period last year.